Free Trial
NASDAQ:SNSE

Sensei Biotherapeutics Q2 2024 Earnings Report

Sensei Biotherapeutics logo
$7.66 +0.18 (+2.41%)
Closing price 04:00 PM Eastern
Extended Trading
$7.26 -0.40 (-5.22%)
As of 06:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sensei Biotherapeutics EPS Results

Actual EPS
-$5.60
Consensus EPS
-$5.80
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

Sensei Biotherapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sensei Biotherapeutics Announcement Details

Quarter
Q2 2024
Time
TAS
Conference Call Date
Tuesday, August 6, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Sensei Biotherapeutics' Q2 2025 earnings is scheduled for Tuesday, August 5, 2025, with a conference call scheduled on Friday, August 1, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sensei Biotherapeutics Earnings Headlines

The Trump Dump is starting; Get out of stocks now?
The first 365 days of the Trump presidency… Will be the best time to get rich in American history.
Sensei Rockets on FY ’24 Results
See More Sensei Biotherapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sensei Biotherapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sensei Biotherapeutics and other key companies, straight to your email.

About Sensei Biotherapeutics

Sensei Biotherapeutics (NASDAQ:SNSE), an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

View Sensei Biotherapeutics Profile

More Earnings Resources from MarketBeat